US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalaris Therapeutics Inc.

6.64

-0.4500-6.35%

Post-market: 6.770.1300+1.96%18:04 EDT

Volume:111.74K

Turnover:768.09K

Market Cap:124.18M

PE:-0.95

High:7.31

Open:7.00

Low:6.62

Close:7.09

52wk High:24.15

52wk Low:2.14

Shares:18.70M

Float Shares:4.31M

Volume Ratio:0.47

T/O Rate:2.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.9936

EPS(LYR):-10.4377

ROE:--

ROA:-681.04%

PB:2.34

PE(LYR):-0.64

Loading ...

Overview Company News Filings

Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week

Simply Wall St.

Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)

BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway

Kalaris Therapeutics Inc - Phase 1B/2 Data Expected in 2H 2026

THOMSON REUTERS

BRIEF-Kalaris Reports Second Quarter 2025 Financial Results And Provides Business Updates

Kalaris Therapeutics Inc - Cash & Cash Equivalents of $88.4M as of June 30, 2025, Expected to Fund Operations Into Q4 2026

THOMSON REUTERS

Kalaris Therapeutics Inc - Net Loss $11.4M or $0.61/Share in Q2 2025

THOMSON REUTERS

Kalaris Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Piper Sandler Initiates Kalaris Therapeutics at Neutral

MT Newswires Live

Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Kalaris Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

William Blair Initiates Kalaris Therapeutics With Outperform Rating

MT Newswires Live

BRIEF-Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee

Press Release: Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KLRS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":6.64,"timestamp":1759521600000,"preClose":7.09,"halted":0,"volume":111741,"hourTrading":{"tag":"盘后","latestPrice":6.77,"preClose":6.64,"latestTime":"18:04 EDT","volume":1514,"amount":10247.83,"timestamp":1759529059815},"delay":0,"floatShares":4309313,"shares":18702418,"eps":-6.993552,"marketStatus":"Market Closed","change":-0.45,"latestTime":"10-03 16:00:00 EDT","open":7,"high":7.31,"low":6.6248,"amount":768087.791131,"amplitude":0.096643,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.993552,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1759737600000},"marketStatusCode":7,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":7.09,"preHourTrading":{"tag":"盘前","latestPrice":7.09,"preClose":7.09,"latestTime":"09:28 EDT","volume":322,"amount":2255.960014,"timestamp":1759498138038},"postHourTrading":{"tag":"盘后","latestPrice":6.77,"preClose":6.64,"latestTime":"18:04 EDT","volume":1514,"amount":10247.83,"timestamp":1759529059815},"volumeRatio":0.4741009735518448},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":4309313,"roa":"-681.04%","roe":"--","lyrEps":-10.437743,"volumeRatio":0.4741009735518448,"shares":18702418,"dividePrice":0,"high":7.31,"amplitude":0.096643,"preClose":7.09,"low":6.6248,"week52Low":2.14,"pbRate":"2.34","week52High":24.15,"institutionHeld":0,"latestPrice":6.64,"eps":-6.993552,"divideRate":0,"volume":111741,"delay":0,"ttmEps":-6.993552,"open":7,"prevYearClose":9.66,"prevWeekClose":5.61,"prevMonthClose":5.78,"prevQuarterClose":5.78,"fiveDayClose":5.61,"twentyDayClose":4.62,"sixtyDayClose":2.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61},{"market":"US","date":"2025-05-14","symbol":"KLRS","fiscalQuarterEnding":"2025/03","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-2.52},{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23},{"market":"US","date":"2024-11-12","symbol":"KLRS","fiscalQuarterEnding":"2024/09","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1756872000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2025-10-03","current":-0.949446,"percent":0.203008,"low":-2.839148,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"high":-0.558935,"avg":-1.052479,"sd":0.547388,"marketCap":132600143},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143}],"updateTime":1759606631871},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2570184060","title":"Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2570184060","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570184060?lang=en_us&edition=fundamental","pubTime":"2025-09-28 20:23","pubTimestamp":1759062236,"startTime":"0","endTime":"0","summary":"Key Insights Kalaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics/news/private-equity-firms-in-kalaris-therapeutics-inc-nasdaqklrs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics/news/private-equity-firms-in-kalaris-therapeutics-inc-nasdaqklrs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","NVIW.SI","TQQQ","USJW.SI","BK4139","NQmain","SQQQ","QID",".IXIC","QLD","USAW.SI","PSQ","TSYW.SI","KLRS"],"gpt_icon":1},{"id":"2568495340","title":"Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568495340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568495340?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:45","pubTimestamp":1758109514,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Marc Goodman from Leerink Partners reiterated a Buy rating on Kalaris Therapeutics, with a price target of $20.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-kalaris-therapeutics-klrs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-kalaris-therapeutics-klrs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2567119024","title":"BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119024","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119024?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:08","pubTimestamp":1757938092,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment UnderwaySept 15 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS NOW ENROLLIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAFMSSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2567197831","title":"Kalaris Therapeutics Inc - Phase 1B/2 Data Expected in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2567197831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567197831?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:00","pubTimestamp":1757937601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAFMSSF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2559336607","title":"BRIEF-Kalaris Reports Second Quarter 2025 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2559336607","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559336607?lang=en_us&edition=fundamental","pubTime":"2025-08-13 21:00","pubTimestamp":1755090044,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Reports Second Quarter 2025 Financial Results And Provides Business UpdatesAug 13 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUABRDLXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2559991604","title":"Kalaris Therapeutics Inc - Cash & Cash Equivalents of $88.4M as of June 30, 2025, Expected to Fund Operations Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559991604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559991604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:00","pubTimestamp":1755086403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUABRDLXJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2559604997","title":"Kalaris Therapeutics Inc - Net Loss $11.4M or $0.61/Share in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559604997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559604997?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:00","pubTimestamp":1755086403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUABRDLXJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2557390026","title":"Kalaris Therapeutics Inc  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557390026","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557390026?lang=en_us&edition=fundamental","pubTime":"2025-08-05 22:53","pubTimestamp":1754405588,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc  expected to post a loss of52cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nL8N3TX2BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS"],"gpt_icon":0},{"id":"2553210120","title":"Piper Sandler Initiates Kalaris Therapeutics at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2553210120","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553210120?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:07","pubTimestamp":1753272464,"startTime":"0","endTime":"0","summary":"Piper Sandler Initiates Kalaris Therapeutics at Neutral","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KLRS"],"gpt_icon":0},{"id":"2535024746","title":"Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535024746","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535024746?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:07","pubTimestamp":1747228077,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryKalaris Therapeutics Inc KLRS.OQ reported a quarterly adjusted loss of $2.52 per share for the quarter ended M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL8N3RM1FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS"],"gpt_icon":0},{"id":"2534644854","title":"Kalaris Therapeutics Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534644854","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534644854?lang=en_us&edition=fundamental","pubTime":"2025-05-10 07:05","pubTimestamp":1746831905,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc  expected to post a loss of77cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to show no change in quarterly revenue when it reports  resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS"],"gpt_icon":0},{"id":"2525989893","title":"William Blair Initiates Kalaris Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2525989893","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525989893?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:20","pubTimestamp":1744111209,"startTime":"0","endTime":"0","summary":"William Blair Initiates Kalaris Therapeutics With Outperform Rating","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KLRS"],"gpt_icon":0},{"id":"2524050452","title":"BRIEF-Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2524050452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524050452?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:02","pubTimestamp":1743768168,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit CommitteeApril 4 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS EXPANDS BOARD OF DIRECTORS APPOINTING LEONE P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nTUAC8B8YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2524741205","title":"Press Release: Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2524741205","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524741205?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth. PALO ALTO, Calif., April 04, 2025  -- Kalaris Therapeutics, Inc.  , a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board's Audit Committee.Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Ph","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","BK4567","PDCO","KLRS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}